Geode Capital Management
VTVT icon

Geode Capital Management’s vTv Therapeutics VTVT Stock Holding History

Geode Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
32,886
+4,692
+17% +$170K ﹤0.01% 3280
2025
Q4 		$1.13M Buy
28,194
+12,896
+84% +$359K ﹤0.01% 3338
2025
Q3 		$356K Buy
15,298
+2,432
+19% +$42.7K ﹤0.01% 3732
2025
Q2 		$190K Buy
12,866
+229
+2% +$4.2K ﹤0.01% 3891
2025
Q1 		$219K Buy
12,637
+1,003
+9% +$16.8K ﹤0.01% 3817
2024
Q4 		$158K Buy
11,634
+1,327
+13% +$19.6K ﹤0.01% 3967
2024
Q3 		$139K Buy
+10,307
New +$171K ﹤0.01% 4015
2023
Q4 		– Sell
-5,903
Closed -$113K – 4683
2023
Q3 		$113K Sell
5,903
-1,331
-18% -$32.6K ﹤0.01% 4207
2023
Q2 		$214K Hold
7,234
– – ﹤0.01% 4015
2023
Q1 		$234K Hold
7,234
– – ﹤0.01% 3969
2022
Q4 		$188K Sell
7,234
-16
-0.2% -$529 ﹤0.01% 4134
2022
Q3 		$281K Sell
7,250
-1,915
-21% -$75.4K ﹤0.01% 4027
2022
Q2 		$274K Buy
9,165
+476
+5% +$12.2K ﹤0.01% 4081
2022
Q1 		$250K Sell
8,689
-2
-0% -$60 ﹤0.01% 4271
2021
Q4 		$345K Hold
8,691
– – ﹤0.01% 4227
2021
Q3 		$531K Buy
8,691
+3,786
+77% +$285K ﹤0.01% 4005
2021
Q2 		$447K Sell
4,905
-1,782
-27% -$181K ﹤0.01% 3992
2021
Q1 		$754K Buy
6,687
+2,431
+57% +$239K ﹤0.01% 3669
2020
Q4 		$316K Buy
4,256
+24
+0.6% +$1.84K ﹤0.01% 3743
2020
Q3 		$299K Buy
4,232
+13
+0.3% +$1.14K ﹤0.01% 3597
2020
Q2 		$379K Buy
4,219
+1,583
+60% +$156K ﹤0.01% 3467
2020
Q1 		$201K Sell
2,636
-186
-7% -$17.9K ﹤0.01% 3551
2019
Q4 		$191K Hold
2,822
– – ﹤0.01% 3811
2019
Q3 		$174K Hold
2,822
– – ﹤0.01% 3821
2019
Q2 		$161K Buy
2,822
+1,019
+57% +$61.2K ﹤0.01% 3845
2019
Q1 		$123K Buy
1,803
+535
+42% +$51.9K ﹤0.01% 3847
2018
Q4 		$134K Hold
1,268
– – ﹤0.01% 3795
2018
Q3 		$39K Sell
1,268
-12
-0.9% -$563 ﹤0.01% 4047
2018
Q2 		$78K Buy
1,280
+188
+17% +$13.9K ﹤0.01% 3921
2018
Q1 		$177K Buy
1,092
+43
+4% +$10.5K ﹤0.01% 3724
2017
Q4 		$252K Buy
1,049
+31
+3% +$6.95K ﹤0.01% 3600
2017
Q3 		$243K Buy
1,018
+46
+5% +$9.17K ﹤0.01% 3604
2017
Q2 		$193K Buy
972
+23
+2% +$4.79K ﹤0.01% 3700
2017
Q1 		$248K Buy
949
+16
+2% +$3.65K ﹤0.01% 3580
2016
Q4 		$180K Buy
933
+15
+2% +$3.45K ﹤0.01% 3651
2016
Q3 		$263K Hold
918
– – ﹤0.01% 3497
2016
Q2 		$212K Buy
918
+46
+5% +$10.6K ﹤0.01% 3572
2016
Q1 		$180 Buy
872
+20
+2% +$4.98K ﹤0.01% 3665
2015
Q4 		$231K Hold
852
– – ﹤0.01% 3623
2015
Q3 		$222K Buy
+852
New +$297K ﹤0.01% 3640

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management's VTVT Position: Q1 2026 in Review

Geode Capital Management increased its vTv Therapeutics (VTVT) stake by 17% in Q1 2026, buying an estimated $170K and bringing the position to 32,886 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Geode Capital Management first reported a position in VTVT in Q3 2015 and has held it in 40 quarters since. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • Geode Capital Management held 32,886 shares of vTv Therapeutics worth $1.31M as of Q1 2026.
  • Geode Capital Management bought 4,692 vTv Therapeutics shares in Q1 2026, an estimated $170K.
  • vTv Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3280 holding.
  • Geode Capital Management first reported a position in vTv Therapeutics in Q3 2015 and has held it in 40 quarters since.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.